| Literature DB >> 35590247 |
Chuyun Chen1, Ying Yang2,3, Wei Ma1,4, Litong Qi1, Baowei Zhang1, Yan Zhang1.
Abstract
BACKGROUND: Left atrial (LA) size is often used as a surrogate marker of LA function in clinical practice, with larger atrial thought to represent a "dysfunctioning" atrium, since there is no accepted 'gold' standard to evaluate LA function. The exact relationship between LA size and phasic function, and whether LA dysfunction occur before LA enlargement (LAE) may be of clinical interest while have not been fully studied. Two-dimensional speckle-tracking echocardiography (2D STE) was showed a promising method in measuring LA physical deformation.Entities:
Keywords: Atrial function; Hypertension; Left atrial remodeling; Phasic function; Speckle tracking
Mesh:
Year: 2022 PMID: 35590247 PMCID: PMC9118856 DOI: 10.1186/s12872-022-02672-z
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.174
Fig. 1Left atrial phasic strain measurements from four-chamber apical view by 2D STE. Sa, peak strain at atrial contraction phase; Se, peak strain at early diastole phase; Stot, total atrial strain (Stot = Sa + Se)
Demographic characteristics of the four study groups
| Variable | Normal LA size (16–34 ml/m2, n = 507) | Mild LAE (35–41 ml/m2, n = 134) | Moderate LAE (42–48 ml/m2, n = 51) | Severe LAE (> 48 ml/m2, n = 23) | |
|---|---|---|---|---|---|
| Age (years) | 65.96 ± 9.11 | 67.75 ± 8.39 | 67.55 ± 7.16 | 70.65 ± 7.90 | 0.016 |
| Gender, male | 47.73% | 48.51% | 62.75% | 65.22% | 0.088 |
| BSA (m2) | 1.84 ± 0.16 | 1.82 ± 0.16 | 1.87 ± 0.18 | 1.85 ± 0.14 | 0.357 |
| BMI (kg/m2) | 25.56 ± 3.29 | 25.50 ± 3.27 | 25.57 ± 3.72 | 25.32 ± 3.12 | 0.986 |
| SBP (mmHg)* | 171.41 ± 19.06 | 177.13 ± 18.50 | 172.13 ± 21.24 | 184.74 ± 18.37 | 0.002 |
| DBP (mmHg)* | 98.83 ± 17.31 | 97.72 ± 17.39 | 97.11 ± 22.04 | 100.79 ± 18.05 | 0.814 |
| HR (beats/min) | 71.07 ± 10.94 | 66.46 ± 10.58 | 65.67 ± 8.93 | 62.13 ± 8.74 | < 0.001 |
| CHD | 7.50% | 12.69% | 13.73% | 13.40% | 0.144 |
| Stroke | 20.71% | 17.91% | 25.49% | 34.78% | 0.256 |
| Peripheral vascular disease | 8.09% | 8.96% | 11.76% | 13.04% | 0.705 |
| HT | 76.73% | 90.30% | 88.24% | 82.61% | 0.002 |
| Diabetes mellitus | 31.95% | 25.37% | 31.37% | 17.39% | 0.257 |
| Smoking | 33.53% | 28.36% | 43.14% | 47.83% | 0.122 |
| Obesity | 20.32% | 20.90% | 21.57% | 17.39% | 0.979 |
| Dyslipidemia | 49.11% | 52.24% | 52.94% | 34.78% | 0.446 |
| Aspirin | 51.48% | 50.00% | 35.29% | 47.83% | 0.179 |
| ACEI | 7.30% | 5.97% | 7.84% | 4.35% | 0.898 |
| ARB | 3.36% | 4.48% | 5.88% | 13.04% | 0.117 |
| Calcium antagonists | 39.25% | 44.78% | 33.33% | 43.48% | 0.484 |
| βblockers | 6.71% | 9.02% | 9.80% | 17.39% | 0.223 |
| Statins | 0.99% | 0.00% | 3.92% | 4.55% | 0.056 |
| Diuretics | 3.35% | 0.75% | 5.88% | 4.35% | 0.257 |
Data are expressed as mean ± SD or as percentage
BSA Body surface area, BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, HR Heart rate, CHD Coronary heart disease, HT Hypertension, ACEI Angiotensin-Converting Enzyme Inhibitor, ARB Angiotensin receptor blocker
*SBP, DBP were only recorded in HT participants. SBP, DBP value above are mean ± SD in HT participants
Conventional echocardiographic characteristics of the four study groups
| Variable | Normal LA size (16–34 ml/m2, n = 507) | Mild LAE (35–41 ml/m2, n = 134) | Moderate LAE (42–48 ml/m2, n = 51) | Severe LAE (> 48 ml/m2, n = 23) | |
|---|---|---|---|---|---|
| LVEDD (cm) | 4.59 ± 0.49 | 4.77 ± 0.49 | 4.88 ± 0.59 | 5.03 ± 0.73 | < 0.001 |
| LVEF (%) | 63.77 ± 6.46 | 63.93 ± 6.98 | 62.41 ± 9.37 | 61.96 ± 11.01 | 0.345 |
| LVSlong (%) | 18.38 ± 3.13 | 18.63 ± 3.34 | 18.45 ± 4.63 | 17.37 ± 4.69 | 0.586 |
| LVMI (g/m2) | 83.34 ± 20.06 | 93.95 ± 23.82 | 94.36 ± 29.29 | 122.47 ± 38.41 | < 0.001 |
| E-wave (cm/s) | 76.05 ± 18.72 | 80.57 ± 20.60 | 83.43 ± 20.29 | 91.13 ± 31.30 | < 0.001 |
| A-wave (cm/s) | 94.29 ± 19.21 | 97.85 ± 29.33 | 91.84 ± 17.64 | 99.73 ± 20.38 | 0.167 |
| E/A retio | 0.83 ± 0.24 | 0.87 ± 0.31 | 0.93 ± 0.27 | 0.88 ± 0.20 | 0.033 |
| E’ (cm/s) | 6.08 ± 1.89 | 5.86 ± 1.73 | 5.98 ± 1.69 | 5.00 ± 1.02 | 0.040 |
| A’ (cm/s) | 10.43 ± 1.85 | 9.75 ± 1.85 | 9.58 ± 2.15 | 8.81 ± 1.94 | < 0.001 |
| E/e’ | 13.30 ± 4.10 | 14.72 ± 5.18 | 14.89 ± 5.57 | 18.74 ± 6.36 | < 0.001 |
| PASP (mmHg) | 28.71 ± 6.33 | 31.08 ± 6.95 | 32.89 ± 9.02 | 33.25 ± 6.67 | < 0.001 |
| LAEF | 0.54 ± 0.08 | 0.54 ± 0.08 | 0.50 ± 0.08 | 0.44 ± 0.13 | < 0.001 |
Data are expressed as mean ± SD
LVEDD Left ventricular end-diastolic dimension, LVEF Left ventricular ejection fraction, LVSlong left ventricle global longitudinal strain, LVMI Left ventricular mass index, PASP Pulmonary artery systolic pressure, LAEF left atrial ejection fraction
Left atrial global phasic strain in different LA size group
| Variable | Normal LA size (16–34 ml/m2, n = 507) | Mild LAE (35–41 ml/m2, n = 134) | Moderate LAE (42–48 ml/m2, n = 51) | Severe LAE (> 48 ml/m2, n = 23) | |
|---|---|---|---|---|---|
| Stot | 21.74 ± 5.97 | 20.75 ± 4.99 | 20.49 ± 5.27 | 17.75 ± 4.71** | 0.003 |
| Se | 9.90 ± 4.58 | 9.74 ± 3.81 | 10.38 ± 4.25 | 9.20 ± 3.06 | 0.719 |
| Sa | 11.84 ± 3.92 | 11.00 ± 3.29* | 10.11 ± 2.57** | 8.55 ± 2.88** | < 0.001 |
Data are expressed as mean ± SD or as percentage
*P < 0.05 versus Normal LA size group
**P < 0.01 versus Normal LA size group
Left atrial global phasic strain in HT and non-HT subgroups with normal left atrial size (n = 507)
| Variable | Non-HT (n = 118) | HT (n = 389) | |
|---|---|---|---|
| Age (year) | 64.00 ± 9.78 | 66.56 ± 8.82 | 0.007 |
| Male (%) | 50.85% | 46.79% | 0.439 |
| LAVI | 25.15 ± 4.55 | 27.14 ± 4.60 | < 0.001 |
| LAEF | 0.55 ± 0.07 | 0.54 ± 0.09 | 0.084 |
| Stot | 23.01 ± 6.02 | 21.35 ± 5.91 | 0.008 |
| Se | 11.17 ± 4.89 | 9.51 ± 4.41 | < 0.001 |
| Sa | 11.84 ± 3.83 | 11.84 ± 3.95 | 0.993 |
Data are expressed as mean ± SD or as percentage
HT Hypertension, LAVI Left atrial volume index, LAEF left atrial ejection fraction
Associations of left atrial functional and structural characteristics
| Variables | ||||||
|---|---|---|---|---|---|---|
| Stot | Se | Sa | ||||
| β | β | β | ||||
| Age | − 0.064 | 0.021 | − 0.040 | 0.031 | ||
| Male | ||||||
| HR | − 0.051 | 0.021 | − 0.048 | 0.006 | ||
| DM | 0.986 | 0.039 | 0.719 | 0.022 | ||
| Smoking | − 1.183 | 0.001 | ||||
| Dyslipidemia | ||||||
| LAVI | − 0.062 | 0.026 | − 0.068 | < 0.001 | ||
| LVSlong | 0.376 | < 0.001 | 0.208 | < 0.001 | 0.169 | < 0.001 |
| E/A | − 1.647 | 0.019 | ||||
| E’ | 0.637 | < 0.001 | − 0.441 | < 0.001 | ||
| A’ | 0.386 | < 0.001 | 0.406 | < 0.001 | ||
| LAEF | 12.316 | < 0.001 | 7.596 | < 0.001 | 4.709 | 0.012 |
| Adjusted R2 | 0.196 | 0.204 | 0.178 | |||
HR Heart rate, DM Diabetes mellitus, LVSlong Left ventricle global longitudinal strain, LAEF left atrial ejection fraction
Fig. 2LA phasic strain in study groups